BiotechTube
Citryll

Citryll

Oss, Netherlands· Est.
citryll.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $113M

Overview

Citryll is a clinical-stage biotech developing CIT-013, a first-in-class monoclonal antibody targeting Neutrophil Extracellular Traps (NETs) to treat immune-mediated inflammatory diseases. The company is currently conducting Phase 2a trials in rheumatoid arthritis (RA) and hidradenitis suppurativa (HS), with a pipeline built on a platform targeting citrullinated histones. Founded in 2015 and based in Oss, Netherlands, Citryll is a private, pre-revenue company aiming to establish a new therapeutic class by intervening upstream of current cytokine-targeting therapies.

Rheumatoid ArthritisHidradenitis SuppurativaImmune-Mediated Inflammatory Diseases

Technology Platform

Monoclonal antibody platform targeting citrullinated histones to inhibit formation and enhance clearance of Neutrophil Extracellular Traps (NETs).

Funding History

4
Total raised:$113M
Series B$60M
Series B$30M
Series A$20M
Seed$3M

Opportunities

CIT-013 targets a root cause of inflammation (NETs) upstream of current cytokine inhibitors, offering potential for broader and more durable efficacy across multiple diseases.
Positive Phase 2a data in RA or HS could validate a new therapeutic class, attracting partnership deals and enabling expansion into other NET-driven indications like lupus and vasculitis.

Risk Factors

The novel NET-targeting mechanism is unproven in late-stage trials, carrying high clinical failure risk.
As a pre-revenue private company, Citryll is dependent on external funding, and development could be halted by capital constraints.
It faces intense competition in crowded inflammatory disease markets from established and novel therapies.

Competitive Landscape

Citryll's primary competition comes from numerous approved biologics and JAK inhibitors in RA and emerging biologics in HS. Its key differentiation is targeting NETs, a shared upstream driver, rather than specific cytokines. A few other early-stage companies are exploring NET inhibition, but Citryll appears to be among the first in clinical trials with a specific anti-citrullinated histone antibody.

More companies in Biologics / Biosimilars →More companies in Netherlands →